Latest Nomenclature Changes in Heart Failure Decompensation
The most significant recent change is the recognition that most "acute decompensated heart failure" hospitalizations are not truly "acute" but represent gradual increases in cardiac filling pressures on preexisting structural heart disease, with the 2022 AHA/ACC/HFSA guidelines now emphasizing assessment of hemodynamic profiles (congestion and perfusion) rather than focusing on the "acute" terminology 1, 2.
Key Nomenclature Evolution
Moving Away from "Acute" Terminology
The 2022 guidelines 1, 2 fundamentally reframe how we conceptualize decompensated heart failure:
- Most HF hospitalizations are NOT truly "acute" but follow a gradual increase of cardiac filling pressures with identifiable precipitating factors
- The emphasis has shifted from the temporal descriptor "acute" to hemodynamic profiling based on congestion severity and perfusion adequacy
- This represents a paradigm shift from viewing decompensation as a sudden event to understanding it as part of the disease trajectory
Proposed Terminology Refinements
Research evidence suggests further nomenclature evolution 3:
- "Acute decompensated chronic HF" (ADCHF) should be renamed "chronic HF exacerbation" (CHFE) to align with terminology used in other chronic organ diseases like COPD
- This reflects that decompensation is part of the natural history of chronic HF, not a separate acute entity
- "Acute HF" should be reserved exclusively for de novo acute HF (new-onset HF requiring urgent attention)
Current Clinical Framework (2022 Guidelines)
The guidelines 1, 2 now structure assessment around:
- Hemodynamic profiling: Severity of congestion + adequacy of perfusion (not "acute vs. chronic")
- Precipitating factors identification (Table 21 lists common triggers: ACS, uncontrolled hypertension, AF, infections, medication nonadherence, anemia, thyroid dysfunction, NSAIDs, negative inotropes)
- Patient trajectory assessment to guide therapy
Important Clinical Distinctions
Up to 1 in 4 patients have mismatched right- and left-sided filling pressures 1, 2:
- Disproportionate right-sided elevation (especially with tricuspid regurgitation) hinders effective decongestion
- Disproportionate left-sided elevation may be underrecognized without jugular venous distention or edema
Standardization Efforts (2024-2026)
Recent consensus documents are working toward:
- Standardized definitions for ADHF evaluation to improve clinical trial generalizability 4
- The Second Universal Definition of Heart Failure (2026) 5 moves away from rigid LVEF cutoffs, grouping HF into reduced, preserved, and improved ejection fraction categories
- Recognition of dynamic HF trajectories: improvement, remission, and recovery
Clinical Implications
The focus has shifted from in-hospital "acute" management to optimal ambulatory chronic HF management aimed at primary and secondary prevention of exacerbations 3. This means:
- Continuing and optimizing GDMT during hospitalization unless contraindicated 1, 2
- Not routinely discontinuing diuresis or GDMT for mild renal function decrease or asymptomatic blood pressure reduction
- Initiating GDMT during hospitalization after clinical stability is achieved
Common Pitfall to Avoid
Do not assume all decompensated HF presentations are the same. De novo acute HF carries higher in-hospital mortality (9.8% vs. 5.5%) and more complications than acute decompensated chronic HF 6, requiring more vigilant monitoring and phenotype-specific management from admission.